[2] [3] In October 2023, the MHRA also approved tirzepatide (Mounjaro) for weight management in adults with an initial BMI of at least 30 kg/m (obesity), or from 27 kg/m to less than 30 kg/m (overweight) in the presence of at least one weight-related comorbidity
Weight loss from Mounjaro may indirectly affect sexual health through hormonal normalisation, improved vascular function, and enhanced psychological wellbeing
Side Effects Both forms share similar semaglutide side effects, primarily gastrointestinal symptoms including nausea (46.6%), vomiting (30.9%), and constipation (20.1%)
Can pregnant or breastfeeding women use this medication
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
Patienten mit verzgerter Magenentleerung (Gastroparese) Wenn Sie eine langsame (verzgerte) Magenentleerung (sogenannte Gastroparese) haben, kann die Anwendung von Semaglutid zu schweren oder schwerwiegenden gastrointestinalen Nebenwirkungen fhren